Significance of adequate acid suppression as part of helicobacter pylori-associated disease therapy
https://doi.org/10.21518/2079-701X-2018-3-18-21
Abstract
The article presents a systematized review of the literature data on the role of adequate acid suppression in the treatment of Helicobacter pylori-associated diseases. The increased pH levels in the stomach correlate with the efficacy of eradication therapy. Thus, minimal inhibitory concentrations of amoxicillin, clarithromycin and metronidazole decrease at higher pH levels, increasing the Helicobacter pylori sensitivity to these antibacterial drugs. In addition, the increased pH levels in the stomach contribute to the stability of some antibacterial agents, which increases the likelihood of eradication success.
About the Authors
D. N. Andreev
Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of Russia
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
A. M. Veliev
Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of Russia
Russian Federation
Russian Federation
References
1. Maev IV, Samsonov AA, Andreev DN. Helicobacter pylori infection. Moscow: GEOTAR-Media, 2016.
2. Morgan DR, Crowe SE. Helicobacter pylori infection. In.: Sleisenger and Fordtran’s Gastro inte sti nal and Liver Disease: Pathophysiology, Diagno sis, Management. Edited by Mark Feldman, Law rence S Friedman, Laurence J Brandt. 10th ed. 2015.
3. Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, Malfertheiner P, Graham DY, Wong VWS, Wu JCY, Chan FKL, Sung JJY, Kaplan GG, Ng SC. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology, 2017, 153(2): 420-429.
4. World Population Clock: 7.6 Billion People (2017) – Worldometers. Available from URL: http: //www.worldometers.info.
5. Ivashkin VT, Maev IV, Lapina TL, Shep tulin AA, Trukhmanov AS, Abdulkhakov RA, Alekseenko SA, Dehnich NN, Kozlov RS, Klyaritskaya IL, Kurilovich SA, Osipenko MF, Simanenkov VI, Khlynov IB. Treatment of Helicobacter pylori infection: mainstream and novation. Ros zhurn gastroenterol gepatol koloproktol, 2017, 27 (4): 4-21.
6. Malfertheiner P, Megraud F, O’Morain CA et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut, 2017, 66(1): 6-30.
7. Fallone CA, Chiba N, van Zanten SV et al. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology, 2016, 151(1): 51-69.
8. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol, 2017, 112(2): 212-239.
9. Zhou L, Sung JJY, Lin S et al. A five-year followup study on the pathological changes of gastric mucosa after H. pylori eradication. Chin Med J, 2003, 116: 11–14.
10. Okubo M, Tahara T, Shibata T et al. Changes in gastric mucosal patterns seen by magnifying NBI during H. pylori eradication. J Gastroenterol, 2011, 46: 175–82.
11. Lee YC, Chen THH, Chiu HM et al. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut, 2013, 62: 676–82.
12. Tsuda M, Asaka M, Kato M, Matsushima R, Fujimori K, Akino K, Kikuchi S, Lin Y, Sakamoto N. Effect on Helicobacter pylori eradication therapy against gastric cancer in Japan. Helicobacter, 2017, 22(5): e12415.
13. Roderick P, Davies R, Raftery J et al. Cost-effectiveness of population screening for Helicobacter pylori in preventing gastric cancer and peptic ulcer disease, using simulation. J Med Screen, 2003, 10: 148–56.
14. Vergara M, Catalán M, Gisbert JP et al. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther, 2005, 21: 1411–18.
15. Maev IV, Andreev DN, Dicheva DT. Gastropathies induced by non-steroidal anti-inflammatory drugs: pathogenetically substantiated approaches to prevention and therapy. Farmateka, 2016, 2: 49-54
16. Andreev D. Helicobacter pylori Eradication Therapy: Current Regimens. Adv Res Gastroentero Hepatol, 2017, 7(2): 555710.
17. Maev IV, Andreev DN, Samsonov AA, Veliev AM. Modern schemes of eradication therapy for Helico bacter pylori infection: a strategy of differentiated use, efficacy and safety. Eksperimental’naya i klinicheskaya gastroenterologiya, 2017, 140 (4): 103-10
18. Zagari RM, Rabitti S, Eusebi LH, Bazzoli F. Treatment of Helicobacter pylori infection: A clinical practice update. Eur J Clin Invest, 2017 Nov 16. doi: 10.1111/eci.12857.
19. Labenz J. Current role of acid suppressants in Helicobacter pylori eradication therapy. Best Pract Res Clin Gastroenterol, 2001, 15: 413–31.
20. De Francesco V, Ierardi E, Hassan C, Zullo A. Helico bacter pylori therapy: Present and future. World J Gastrointest Pharmacol Ther, 2012, 3(4): 68-73.
21. Erah PO, Goddard AF, Barrett DA, Shaw PN, Spiller RC. The stability of amoxycillin, clarithro mycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother, 1997, 39(1): 5-12.
22. Sugimoto M, Furuta T, Shirai N et al. Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter,2007, 12(4): 317–323.
23. Manes G, Pieramico O, Perri F et al. Twice daily standard dose of omeprazole achieves the necessary level of acid inhibition for Helicobacter pylori eradication. A randomized controlled trial using standard and double doses of omeprazole in triple therapy. Dig Dis Sci, 2005, 50(3): 443–448.
24. Chang CS, Yang CY, Wong FN, Chen GH, Lien HC, Yeh HZ, Poon SK. The effect of intragastric acidity on Helicobacter pylori eradication with bismuth-metronidazole-amoxicillin. Hepatogastroenterology, 1999 Jul-Aug, 46(28): 2713-7.
25. Osefo N, Ito T, Jensen RT. Gastric acid hypersecretory states: recent insights and advances. Curr Gastroenterol Rep, 2009, 11(6): 433-41.
26. Maev IV, Andreev DN, Kucheryavyi YuA, Dicheva DT. Host factors influencing the eradication rate of Helicobacter pylori. World Applied Sci J, 2014, 30: 134-140.
27. Maev IV, Andreev DN. Molecular genetic predictors of resistance to anti-Helicobacter therapy. Terapevticheskiy Arkhiv, 2017, 89 (8): 5-12
28. Beales IL, Calam J. Interleukin 1 beta and tumour necrosis factor alpha inhibit acid secretion in cultured rabbit parietal cells by multiple pathways. Gut, 1998, 42(2): 227-34.
29. Furuta T, Shirai N, Takashima M, Xiao F, Sugimura H. Effect of genotypic differences in interleukin-1 beta on gastric acid secretion in Japanese patients infected with Helicobacter pylori. Am J Med, 2002, 112(2): 141-3.
30. Maev IV, Kucheryavy Yu.A., Oganesyan TS. Allelic poly-morphism of interleukin-1β in helicobacterio-sis. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii, 2008, 18 (5): 4-11
31. Sugimoto M, Furuta T, Yamaoka Y. Influence of inflammatory cytokine polymorphisms on eradication rates of Helicobacter pylori. J Gastroenterol Hepatol, 2009 Nov, 24(11): 1725-32.
32. Kucheryavy YuA, Barkalova EV. Double doses of proton pump inhibitors: a way to increase the efficacy of triple therapy for the first-line anti-H.pylori treatment. Lechebnoe Delo, 2012, 1: 36-42
33. Vallve M, Vergara M, Gisbert JP et al. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. Aliment Pharmacol Ther, 2002, 16: 1149–56.
34. Villoria A, Garcia P, Calvet X et al. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther, 2008, 28: 868–77.
35. Andreev DN, Dicheva DT, Maev IV. Possibilities of optimization of Helicobacter pylori eradication therapy in modern clinical practice. Terapevticheskiy Arkhiv, 2017, 2: 76-83.
36. Kucheryavyy YuA, Andreev DN. Prospects for treatment for patients with acid-dependent diseases. Klin. Perspektivy Gastroenterol., Gepatol, 2014, 2: 15-24
37. Andreev DN, Kucheryavy YuA. Prospects for treatment for gastroesophageal reflux disease. Gastroenterologiya. Appendix to the Journal Consilium Medicum, 2013, 2: 9-14.
38. Martinucci I, Blandizzi C, Bodini G, Marabotto E, Savarino V, Marchi S, de Bortoli N, Savarino E. Vonoprazan fumarate for the management of acid-related diseases. Expert Opin Pharmacother, 2017, 18(11): 1145-1152.
39. Akazawa Y, Fukuda D, Fukuda Y. Vonoprazan-based therapy for Helicobacter pylori eradication: experience and clinical evidence. Therap Adv Gastroenterol, 2016, 9(6): 845-852.
40. Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut, 2016, 65(9): 1439-1446.
41. McNicholl AG, Linares PM, Nyssen OP, Calvet X, Gisbert JP. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther, 2012, 36(5): 414–425.
42. Zaborovsky AV, Maev IV, Andreev DN, Tararina LA. Pleiotropic effects of rabeprazole and their role in the treatment of patients with acid-dependent diseases. Rossiysky Zhurnal Gastroenterologii, Gepatologii, Koloproktologii, 2017, 27 (3): 18-26.
43. Desta ZX, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet., 2002, 41(12): 913–958. DOI: 10.2165/00003088-200241120-00002.
44. Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol, 2010, 69(3): 222-30. DOI: 10.1111/j.1365-2125.2009.03578.x.
45. Serrano D, Torrado S, Torrado-Santiago S, Gisbert JP. The influence of CYP2C19 genetic polymorphism on the pharmacokinetics/pharmacodynamics of proton pump inhibitor-containing Helicobacter pylori treatments. Curr Drug Metab, 2012, 13(9): 1303-12. DOI: 10.2174/138920012803341393.
46. Chaudhry AS, Kochhar R, Kohli KK. Genetic pol-ymorphism of CYP2C19 & therapeutic response to proton pump inhibitors. Indian J. Med. Res., 2008, 127(6): 521–530.
47. Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol, 2006, 101(7): 1467-75.
48. Kuo CH, Lu CY, Shih HY, Liu CJ, Wu MC, Hu HM, Hsu WH, Yu FJ, Wu DC, Kuo FC. CYP2C19 poly-morphism influences Helicobacter pylori eradication. World J Gastroenterol, 2014 Nov 21, 20(43): 16029-36.
49. Denisenko NP, Sychev DA, Sizova ZhM, Grachev AV, Velikolug KA. High frequency of CYP2C19 ultrarapid metabolizers in Russian patients with peptic ulcer. Eksp Klin Gastroenterol, 2015, 6: 11-5.
Review
For citations:
Andreev DN, Veliev AM. Significance of adequate acid suppression as part of helicobacter pylori-associated disease therapy. Meditsinskiy sovet = Medical Council. 2018;(3):18-21. (In Russ.) https://doi.org/10.21518/2079-701X-2018-3-18-21
Views:
916
Email this article 